AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32978034 — intervention group
Group type: COMPARATOR
Intervention: Enriched Acceptance and Commitment Therapy (EnACT)
Number of subjects: 38
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic fixation
Number of subjects: 486
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical technique of open reduction and internal fixation
Number of subjects: 486
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to walk at presentation
Number of subjects: 486
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated opposite hips
Number of subjects: 486
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Age under 12.5 years
Number of subjects: 486
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical strategy variation
Number of subjects: 486
Study 35360942 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs)
Number of subjects: 486
Study 33678038 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention administered by an unblinded nurse falls care manager
Number of subjects: 0
Study 33678038 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised primary outcome definition (Types 1 and 2a)
Number of subjects: 0
Study 33678038 — intervention group
Group type: EXPERIMENTAL
Intervention: Original primary outcome definition (Types 1, 2a, and 2b)
Number of subjects: 0
Study 33678038 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control)
Number of subjects: 0
Study 35617770 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adiposity (WC > 88 cm)
Number of subjects: 621
Study 35617770 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adiposity (WHR > 0.8)
Number of subjects: 621
Study 33152350 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 22
Study 33152350 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM
Number of subjects: 22
Study 33152350 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM/IVF
Number of subjects: 22
Study 32928140 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ED-centered recruitment strategy
Number of subjects: 120
Study 32928140 — intervention group
Group type: COMPARATOR
Intervention: Standard recruitment strategy (pre-enhancement)
Number of subjects: 120
Study 32928140 — intervention group
Group type: EXPERIMENTAL
Intervention: Total recruitment period
Number of subjects: 120
Study 33453489 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born before 28 weeks GA
Number of subjects: 74
Study 33453489 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with late-onset septicaemia (LOS)
Number of subjects: 74
Study 33453489 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with bronchopulmonary dysplasia (BPD)
Number of subjects: 74
Study 33453489 — intervention group
Group type: COMPARATOR
Intervention: VLBW infants
Number of subjects: 74
Study 32063029 — intervention group
Group type: EXPERIMENTAL
Intervention: New experimental arms added to ongoing trials
Number of subjects: 0
Study 32063029 — intervention group
Group type: COMPARATOR
Intervention: Existing control arm
Number of subjects: 0
Study 32063029 — intervention group
Group type: EXPERIMENTAL
Intervention: Šidák’s correction
Number of subjects: 0
Study 33257497 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 354
Study 33257497 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 354
Study 32879436 — intervention group
Group type: EXPERIMENTAL
Intervention: DSC2U (Down Syndrome Clinic to You)
Number of subjects: 230
Study 32879436 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study 36366791 — intervention group
Group type: EXPERIMENTAL
Intervention: Teach-Back intervention (TIME)
Number of subjects: 107
Study 36366791 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 107
Study 34881935 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT/CBT
Number of subjects: 123
Study 34881935 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoid/CBT
Number of subjects: 123
Study 34881935 — intervention group
Group type: COMPARATOR
Intervention: WL/TAU
Number of subjects: 123
Study 35313936 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.25% bupivacaine (total 50 mg) for bilateral ultrasound-guided rectus sheath block (URSB)
Number of subjects: 66
Study 35313936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sham block)
Number of subjects: 66
Study 33580845 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (4 g twice daily)
Number of subjects: 53
Study 33580845 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glycine, 4 g twice daily)
Number of subjects: 53
Study 36175252 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-bundle anterior cruciate ligament reconstruction
Number of subjects: 25
Study 36175252 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle anterior cruciate ligament reconstruction
Number of subjects: 25
Study 33393638 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal inpatient rehabilitation with workplace intervention
Number of subjects: 175
Study 33393638 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient occupational rehabilitation without workplace intervention
Number of subjects: 175
Study 33393638 — intervention group
Group type: EXPERIMENTAL
Intervention: High or medium self-efficacy scores
Number of subjects: 175
Study 33393638 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistently high or increasing self-efficacy scores
Number of subjects: 175
Study 33584534 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabby (online conversational agent)
Number of subjects: 480
Study 33584534 — intervention group
Group type: COMPARATOR
Intervention: Control group (letter listing preconception risks)
Number of subjects: 480
Study 33558360 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 50
Study 33558360 — intervention group
Group type: COMPARATOR
Intervention: Colesevelam (Bile Acid Sequestrant)
Number of subjects: 50
Study 32065857 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 32065857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Number of subjects: 0
Study 32065857 — intervention group
Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 0
Study 35266279 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Reflection Resilience Training
Number of subjects: 68
Study 35266279 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 68
Study 32293314 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Care Transition Module (RCTM)
Number of subjects: 240
Study 32293314 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 240
Study 35381657 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological suggestion combined with rational diet therapy
Number of subjects: 181
Study 35381657 — intervention group
Group type: COMPARATOR
Intervention: Routine dietary guidance and health education (Control)
Number of subjects: 181
Study 34313371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg b.i.d.
Number of subjects: 43
Study 34085547 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm distension fluid (37°C)
Number of subjects: 100
Study 34085547 — intervention group
Group type: COMPARATOR
Intervention: Room temperature fluid (25°C)
Number of subjects: 100
Study 34085547 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 33037609 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium NaCl (0.4 g/100 mL) + 29 mM MSG
Number of subjects: 115
Study 33037609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl (0.2 g/100 mL) + 29 mM MSG
Number of subjects: 115
Study 33037609 — intervention group
Group type: COMPARATOR
Intervention: Control broth (0 g NaCl, 0 g MSG)
Number of subjects: 115
Study 33037609 — intervention group
Group type: EXPERIMENTAL
Intervention: High NaCl broth (0.8 g/100 mL)
Number of subjects: 115
Study 33037609 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium NaCl (0.4 g/100 mL)
Number of subjects: 115
Study 33037609 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NaCl (0.2 g/100 mL)
Number of subjects: 115
Study 33938708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment after dermabrasion
Number of subjects: 40
Study 33938708 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone gel after dermabrasion
Number of subjects: 40
Study 34233907 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume guarantee (VG)
Number of subjects: 19
Study 34233907 — intervention group
Group type: COMPARATOR
Intervention: Volume controlled ventilation (VCV)
Number of subjects: 19
Study 34670544 — intervention group
Group type: EXPERIMENTAL
Intervention: Microthreaded implants
Number of subjects: 30
Study 34670544 — intervention group
Group type: COMPARATOR
Intervention: Threaded implants
Number of subjects: 30
Study 32401221 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference follow-up
Number of subjects: 120
Study 32401221 — intervention group
Group type: COMPARATOR
Intervention: Telephone follow-up
Number of subjects: 120
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory agents
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1627
Study 34474088 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 1627
Study 32998775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine lavage
Number of subjects: 60
Study 32998775 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppository
Number of subjects: 60
Study 32998775 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 60
Study 32998775 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 34467629 — intervention group
Group type: EXPERIMENTAL
Intervention: Education pack to clean umbilicus prior to surgery
Number of subjects: 62
Study 34467629 — intervention group
Group type: COMPARATOR
Intervention: No education pack (control group)
Number of subjects: 62
Study 32624366 — intervention group
Group type: EXPERIMENTAL
Intervention: Light transmittance aggregometry (LTA)
Number of subjects: 249
Study 32624366 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboelastography (TEG)
Number of subjects: 249
Study 32624366 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function analyzer (PFA)
Number of subjects: 249
Study 32624366 — intervention group
Group type: COMPARATOR
Intervention: Control group (clopidogrel users)
Number of subjects: 249
Study 35272779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance
Number of subjects: 150
Study 35272779 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance alone
Number of subjects: 150
Study 35272779 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) guidance with drug-coated balloons
Number of subjects: 150
Study 35272779 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance with drug-coated balloons
Number of subjects: 150
Study 33397768 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 4.5 mg
Number of subjects: 1842
Study 33397768 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 3.0 mg
Number of subjects: 1842
Study 33397768 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1842
Study 34287760 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term absorbable suture (MonoPlus®) - Group I
Number of subjects: 104
Study 34287760 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term absorbable suture and onlay mesh reinforcement - Group II
Number of subjects: 104
Study 34287760 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra long-term absorbable suture (MonoMax®) - Group III
Number of subjects: 104
Study 34287760 — intervention group
Group type: COMPARATOR
Intervention: Control group (Primary suture)
Number of subjects: 104
Study 34386735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 50 mg
Number of subjects: 15
Study 34386735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 34386735 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin vs Placebo
Number of subjects: 15
Study 34386735 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin and Placebo
Number of subjects: 15
Study 35250807 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprasensory RPSS (one session)
Number of subjects: 0
Study 35250807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsensory RPSS (one session)
Number of subjects: 0
Study 33082245 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 2139
Study 35263104 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet based on crops fertilized with animal manure
Number of subjects: 33
Study 35263104 — intervention group
Group type: COMPARATOR
Intervention: Synthetic fertilizer
Number of subjects: 33
Study 35259523 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 68
Study 35259523 — intervention group
Group type: COMPARATOR
Intervention: Reading/listening intervention (READ)
Number of subjects: 68
Study 32755236 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective recall of 90‐day modified Rankin Scale at 6, 9, or 12 months after hospital discharge
Number of subjects: 0
Study 34281014 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-Performed Music Therapy (LPMT)
Number of subjects: 45
Study 34281014 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 45
Study 36380186 — intervention group
Group type: EXPERIMENTAL
Intervention: B. clausii (oral suspension, total dose 4 billion spores/day)
Number of subjects: 259
Study 36380186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study 36380186 — intervention group
Group type: EXPERIMENTAL
Intervention: B. clausii
Number of subjects: 259
Study 36380186 — intervention group
Group type: COMPARATOR
Intervention: B. clausii and Placebo
Number of subjects: 259
Study 32224739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) at a dose of 15 mg/kg
Number of subjects: 5698
Study 32224739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 5698
Study 32224739 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 5698
Study 32595959 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal processing-based auditory training program (36 sessions over three months)
Number of subjects: 0
Study 32595959 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 36301983 — intervention group
Group type: EXPERIMENTAL
Intervention: standard care + online parent training
Number of subjects: 90
Study 36301983 — intervention group
Group type: EXPERIMENTAL
Intervention: standard care + face-to-face parent training
Number of subjects: 90
Study 36301983 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 90
Study 34932280 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol intravenously 500 mg once daily for 14 days, followed by Mexidol FORTE 250 - 250 mg 3 times a day orally for 60 days
Number of subjects: 318
Study 34932280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 34399839 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl chloride foil containing an integrated silver-based agent (2% silver ions) applied to high-touch surfaces
Number of subjects: 0
Study 34399839 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard cleaning and disinfection)
Number of subjects: 0
Study 33228714 — intervention group
Group type: EXPERIMENTAL
Intervention: HOGO system (EMF-insulated bed) for 2 months
Number of subjects: 31
Study 33228714 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (bed without EMF insulation)
Number of subjects: 31
Study 36353150 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point acupressure (APA), applied 4 times/day for three weeks
Number of subjects: 68
Study 36353150 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 68
Study 32472804 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy
Number of subjects: 283
Study 32472804 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy
Number of subjects: 283
Study 36378780 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil (87.5 mg po BID)
Number of subjects: 400
Study 36378780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 32795214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing medicine randomized controlled trials (RCTs) in Europe
Number of subjects: 106
Study 32795214 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing medicine randomized controlled trials (RCTs) in the USA
Number of subjects: 106
Study 32795214 — intervention group
Group type: COMPARATOR
Intervention: European trials
Number of subjects: 106
Study 32795214 — intervention group
Group type: COMPARATOR
Intervention: USA trials
Number of subjects: 106
Study 32795214 — intervention group
Group type: COMPARATOR
Intervention: Multicenter trials in Europe
Number of subjects: 106
Study 32795214 — intervention group
Group type: COMPARATOR
Intervention: Multicenter trials in the USA
Number of subjects: 106
Study 32795214 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked RCTs in the USA
Number of subjects: 106
Study 32795214 — intervention group
Group type: COMPARATOR
Intervention: Masked RCTs in Europe
Number of subjects: 106
Study 32795214 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs on hospitalized patients in Europe
Number of subjects: 106
Study 32795214 — intervention group
Group type: COMPARATOR
Intervention: RCTs on hospitalized patients in the USA
Number of subjects: 106
Study 35881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 446
Study 35881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fatigue levels
Number of subjects: 446
Study 35881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline emotional functioning
Number of subjects: 446
Study 35881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exercise habits
Number of subjects: 446
Study 35881067 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Number of subjects: 446
Study 33594278 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled low-dose memory (CD45RA-depleted) donor lymphocyte infusion (mDLI)
Number of subjects: 149
Study 33594278 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 149
Study 33594278 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort
Number of subjects: 149
Study 33594278 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory DLI
Number of subjects: 149
Study 35351716 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised digital behaviour change intervention delivered via app
Number of subjects: 205
Study 35351716 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 205
Study 33086387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial short-term infusion chemotherapy via angiocatheters or implanted arterial port catheters, infusion time of 7 to 12 minutes.
Number of subjects: 55
Study 32881054 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE) - 35 minutes at 60%-65% of peak heart rate (HRmax)
Number of subjects: 12
Study 32881054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE 1) - 60×(8-s cycling-12-s recovery) at 80%-90% of HRmax
Number of subjects: 12
Study 32881054 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Exercise (HIIE 2) - 10×1min at 80%-90% of HRmax - 1-min recovery
Number of subjects: 12
Study 34958721 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (5.8%) injection
Number of subjects: 34
Study 34958721 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) injection
Number of subjects: 34
Study 34958721 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (3 min isometric wall squat)
Number of subjects: 34
Study 34704715 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch block (MBB) during PKP surgery, injection of lidocaine and budesonide
Number of subjects: 198
Study 34704715 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial branch block (MBB) during PKP surgery
Number of subjects: 198
Study 34704715 — intervention group
Group type: COMPARATOR
Intervention: Non-MBB group (normal saline injection during PKP surgery)
Number of subjects: 198
Study 35416374 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cycles of induction chemotherapy with platinum and docetaxel (TP) plus a Bcl‐2 inhibitor
Number of subjects: 54
Study 35416374 — intervention group
Group type: COMPARATOR
Intervention: Single cycle induction chemotherapy with platinum and 5‐flurouracil (PF)
Number of subjects: 54
Study 33628786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascaris lumbricoides
Number of subjects: 788
Study 33628786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm
Number of subjects: 788
Study 33628786 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris trichiura
Number of subjects: 788
Study 33628786 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillaria hepatica
Number of subjects: 788
Study 33628786 — intervention group
Group type: EXPERIMENTAL
Intervention: Double parasitism (Ascaris lumbricoides + Trichuris trichiura)
Number of subjects: 788